key: cord-0890215-a0s74x4m
authors: Nakamura, Hideta; Miyagi, Kazuya; Otsuki, Mariko; Higure, Yuri; Nishiyama, Naoya; Kinjo, Takeshi; Nakamatsu, Masashi; Haranaga, Shusaku; Tateyama, Masao; Fujita, Jiro
title: Serum KL‐6 can distinguish between different phenotypes of severe COVID‐19
date: 2020-07-07
journal: J Med Virol
DOI: 10.1002/jmv.26268
sha: 6ffea1dd16c0370d9f660f7783e6a9cd84f80360
doc_id: 890215
cord_uid: a0s74x4m

We read the article by D'Alessandro Miriana et al. with great interest and appreciate their efforts to evaluate the role of serum Krebs von den Lungen‐6 (KL‐6) as a prognostic biomarker of severe coronavirus disease 2019 (COVID‐19).(1) This article is protected by copyright. All rights reserved.

working group reported that patients with type L COVID-19 do not display increased serum KL-6. 5 Since biomarker detection in these studies 1, 5 was performed at admission, changes in KL-6 during COVID-19 infection remain unexamined. We hypothesized that KL-6 could help distinguish the L and H types of severe COVID-19 during its clinical course. Here, we report different serum KL-6 kinetics in two patients with severe COVID-19. Serum KL-6 was measured at admission (day 1), and on days 7, 14, and 21. 

These cases reveal different kinetics of serum KL-6 levels in two critically ill patients with COVID-19. In ILDs, elevated KL-6 reflects the progression of lung volume loss. 6 IPF prognosis is significantly worse when KL-6 exceeds 1,000 U/mL, 3 and the Italian COVID-19 study produced consistent results. 1 The continuous increase in serum KL-6 in case 2 was probably correlated with changes in lung elastance, as a follow-up chest CT on day 31 revealed bronchiole dilation accompanied by extensive bilateral consolidation.

The results suggest that cases 1 and 2 were type L and H, respectively.

The kinetics of KL-6 in case 1 may be explained by the pathology of organizing pneumonia (OP), which produces radiographic patterns similar to COVID-19. 7 KL-6 levels can fluctuate in OP, 8 as damage to type II pneumocytes is typically influenced by underlying conditions. 9 Inflammatory debris in the alveolar space can affect lung compliance as well as gas exchange, but anti-inflammatory agents are expected to cause rapid clearance unless severe type II pneumocyte impairment develops. Perhaps type L CARDS retains intact type II pneumocytes. As SARS-Cov-2 infects type II pneumocytes, 10 the case displaying no elevation in KL-6 is intriguing.

This article is protected by copyright. All rights reserved.

Serum KL-6 concentrations as a novel biomarker of severe COVID-19

New serum indicator of interstitial pneumonitis activity. Sialyated carbohydrate antigen KL-6

We would like to thank Editage (www. editage.com) for English language editing.

Authorship: All authors contributed to the letter.

Accepted Article